Mycobacterium Citations List: August 2023
Literature Citations
1. GC-MS Profiling of Vitex pinnata Bark Lipophilic Extract and Screening of its anti-TB and Cytotoxic Activities. Abdelbaset, S., D.M. El-Kersh, I.M. Ayoub, and O.A. Eldahshan. Natural Product Research, 2023. 37(16): p. 2718-2724. PMID[36110061].
[PubMed]. TB_08_2023.
2. Synthesis and Anti-tuberculosis Activity of 2- (2-Hydroxy-4-trifluoromethyl-phenylamino)-methylene -cyclohexane-1,3-dione. Ahad, R., N.A. Lone, A.I. Bhat, and A.M. Lone. Latin American Journal of Pharmacy, 2023. 42(6): p. 1196-1199. ISI[001019683900009].
[WOS]. TB_08_2023.
3. Biochemical Characterization of Mycobacterium tuberculosis Dihydroorotate dehydrogenase and Identification of a Selective Inhibitor. Alberti, M., S. Sainas, E. Ronchi, M.L. Lolli, D. Boschi, M. Rizzi, D.M. Ferraris, and R. Miggiano. FEBS Letters, 2023. 597(16): p. 2119-2132. PMID[37278160].
[PubMed]. TB_08_2023.
4. Synthesis, Docking Studies, and Biological Evaluation of Some New 4-(1H-Pyrrol-1-yl) benzohydrazide Schiff Bases. Avunoori, S., M.H. Mahnashi, A.M. Momenah, I.A. Shaikh, V.H. Kulkarni, and S.D. Joshi. Indian Journal of Heterocyclic Chemistry, 2023. 33(2): p. 233-239. ISI[001036884700013].
[WOS]. TB_08_2023.
5. Discovery of New Diaryl ether Inhibitors Against Mycobacterium tuberculosis Targeting the Minor Portal of InhA. Chebaiki, M., E. Delfourne, R. Tamhaev, S. Danoun, F. Rodriguez, P. Hoffmann, E. Grosjean, F. Goncalves, J. Azéma-Despeyroux, A. Pál, J. Korduláková, N. Preuilh, S. Britton, P. Constant, H. Marrakchi, L. Maveyraud, L. Mourey, and C. Lherbet. European Journal of Medicinal Chemistry, 2023. 259: 115646. PMID[37482022].
[PubMed]. TB_08_2023.
6. Chemical Analysis and Antitubercular Activity Evaluation of the Dried Mycelial Powders of the Basidiomycete Ganoderma australe TBRC-BCC 22314. Chinthanom, P., K. Dokladda, V. Vichai, R. Choeyklin, C. Thongpanchang, and M. Isaka. Fitoterapia, 2023. 169: 105597. PMID[37380134].
[PubMed]. TB_08_2023.
7. Antimicrobial Activities of Substituted 4-N-Alkylated-2-trifluoromethylquinoline Analogs against Nontuberculous Mycobacteria. da Silva, E.T., G.F. de Andrade, M.C.S. Lourenco, and M.V.N. de Souza. Letters in Drug Design & Discovery, 2023. 20(11): p. 1861-1866. ISI[001037448300014].
[WOS]. TB_08_2023.
8. Antimycobacterial and Nitric oxide Production Inhibitory Activities of Limonoids Isolated from Trichilia lepidota Subsp. Schumanniana (Harms) T.D.Penn. de Souza Passos, M., T.S.R. Nogueira, R.R. da Silva Robaina, S.D. Calixto, T. Simão, M.F. Muzitano, E. Lassounskaia, R. Braz-Filho, and I.J. Curcino Vieira. Phytochemistry, 2023. 214: 113818. PMID[37558193].
[PubMed]. TB_08_2023.
9. 3-Methoxy-2-phenylimidazo[1,2-b]pyridazines Highly Active against Mycobacterium tuberculosis and Mycobacterium marinum. Farrell, K.D., Y. Gao, D.A. Hughes, R. Henches, Z. Tu, M.V. Perkins, T. Zhang, and C.L. Francis. European Journal of Medicinal Chemistry, 2023. 259: 115637. PMID[37524009].
[PubMed]. TB_08_2023.
10. Antibacterial Activity of the Novel Oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus. Gao, S., W. Nie, L. Liu, L. Su, Y. You, R. Geng, and N. Chu. Frontiers in Cellular and Infection Microbiology, 2023. 13: 1225341. PMID[37655300]. PMCID[PMC10465794].
[PubMed]. TB_08_2023.
11. Synthesis and Biological Evaluation of 2-(Tetrazol-5-yl)sulfonylacetamides as Inhibitors of Mycobacterium tuberculosis and Mycobacterium marinum. Henches, R., T. Ozga, Y. Gao, Z. Tu, T. Zhang, and C.L. Francis. Bioorganic & Medicinal Chemistry Letters, 2023. 92: 129391. PMID[37369331].
[PubMed]. TB_08_2023.
12. Additive Effects of Cyclic Peptide [R4W4] When Added Alongside Azithromycin and Rifampicin against Mycobacterium avium Infection. Kelley, M., K. Sasaninia, A. Abnousian, A. Badaoui, J. Owens, A. Beever, N. Kachour, R.K. Tiwari, and V. Venketaraman. Pathogens, 2023. 12(8): 1057. PMID[37624017]. PMCID[PMC10459066].
[PubMed]. TB_08_2023.
13. New Phocoenamicin and Maklamicin Analogues from Cultures of Three Marine-derived Micromonospora Strains. Kokkini, M., D. Oves-Costales, P. Sánchez, Á. Melguizo, T.A. Mackenzie, M. Pérez-Bonilla, J. Martín, A. Giusti, P. de Witte, F. Vicente, O. Genilloud, and F. Reyes. Marine Drugs, 2023. 21(8): 443. PMID[37623724]. PMCID[PMC10455904].
[PubMed]. TB_08_2023.
14. Green and Efficient Three-component Synthesis of Novel Isoniazid Pyrazoles, Molecular Docking, Antioxidant and Antitubercular Evaluation. Koli, B.P., R.P. Gore, and P.R. Malasane. Synthetic Communications, 2023. 53(18): p. 1506-1519. ISI[001029379500001].
[WOS]. TB_08_2023.
15. Development of Tetracycline-modified Nanoparticles for Bone-targeted Delivery of Anti-tubercular Drug. Liang, Q., P. Zhang, L. Zhang, H. Luan, X. Li, H. Xiang, S. Jing, and X. Song. Frontiers in Bioengineering and Biotechnology, 2023. 11: 1207520. PMID[37635999]. PMCID[PMC10450143].
[PubMed]. TB_08_2023.
16. Design, Synthesis, and In Vitro Biological Evaluation of ROS-generating Phenanthridin-trione-epoxide Conjugates as Agents Against Mycobacterium tuberculosis. Mamgain, R., S. Swami, D. Sarkar, and P. Srivastava. ChemistrySelect, 2023. 8(25): e202300416. ISI[001031473400055].
[WOS]. TB_08_2023.
17. Tetrahydroisoquinoline Based 5-Nitro-2-furoic acid Derivatives: A Promising New Approach for Anti-tubercular Agents. Nandikolla, A., Y.M. Khetmalis, G.P.V. Sangeetha, A. Chandu, Swati, M.M.K. Kumar, V. Sharma, S. Murugesan, and K. Sekhar. New Journal of Chemistry, 2023(32): p. 15378-15389. ISI[001042038800001].
[WOS]. TB_08_2023.
18. Design, Synthesis and Biological Evaluation of Phenanthridine amide and 1,2,3-Triazole Analogues against Mycobacterium tuberculosis. Nandikolla, A., Y.M. Khetmalis, B. Venkata Siva Kumar, A. Chandu, B. Karan Kumar, G. Shetye, R. Ma, S. Murugesan, S.G. Franzblau, and K.V.G. Chandra Sekhar. RSC Medicinal Chemistry, 2023. 14(8): p. 1549-1561. PMID[37593576]. PMCID[PMC10429663].
[PubMed]. TB_08_2023.
19. Antimycobacterial Pyridine carboxamides: From Design to In Vivo Activity. Nawrot, D.E., G. Bouz, O. Janďourek, K. Konečná, P. Paterová, P. Bárta, M. Novák, R. Kučera, J. Zemanová, M. Forbak, J. Korduláková, O. Pavliš, P. Kubíčková, M. Doležal, and J. Zitko. European Journal of Medicinal Chemistry, 2023. 258: 115617. PMID[37423128].
[PubMed]. TB_08_2023.
20. Novel Pyrimidine-1,3,4-oxadiazole Hybrids and Their Precursors as Potential Antimycobacterial Agents. Pflégr, V., J. Stolaříková, A. Pál, J. Korduláková, and M. Krátký. Future Medicinal Chemistry, 2023. 15(12): p. 1049-1067. PMID[37555280].
[PubMed]. TB_08_2023.
21. Novel Pyrimidine-imines Against Tuberculosis: Rationale, In Vitro, In Silico Studies and Mechanistic Insights. Ramesh, D., D. Chattopadhyay, S. Kumari, B.G. Vijayakumar, M.T. Gupta, A.K. Pinnaka, D. Sriram, and T. Kannan. Journal of Molecular Structure, 2023. 1292: 136183. ISI[001046844900001].
[WOS]. TB_08_2023.
22. Synthesis, Antimycobacterial Screening, Molecular Docking, ADMET Prediction and Pharmacological Evaluation on Novel Pyran-4-one Bearing Hydrazone, Triazole and Isoxazole Moieties: Potential Inhibitors of SARS CoV-2. Ravisankar, N., N. Sarathi, T. Maruthavanan, S. Ramasundaram, M. Ramesh, C. Sankar, S. Umamatheswari, G. Kanthimathi, and T.H. Oh. Journal of Molecular Structure, 2023. 1285: 135461. PMID[37041803]. PMCID[PMC10062711].
[PubMed]. TB_08_2023.
23. UHPLC-QQQ-MS and RP-HPLC Detection of Bioactive Alizarin and Scopoletin Metabolites from Morinda citrifolia Root Extracts and their Antitubercular, Antibacterial, and Antioxidant Activities. Sam-Ang, P., A. Phanumartwiwath, D. Liana, S. Sureram, P. Hongmanee, and P. Kittakoop. ACS Omega, 2023. 8(32): p. 29615-29624. PMID[37599981]. PMCID[PMC10433487].
[PubMed]. TB_08_2023.
24. Design, Synthesis, and Evaluation of Novel Δ(2)-Thiazolino 2-pyridone Derivatives that Potentiate Isoniazid Activity in an Isoniazid-resistant Mycobacterium tuberculosis Mutant. Sarkar, S., A.E. Mayer Bridwell, J.A.D. Good, E.R. Wang, S.R. McKee, J. Valenta, G.A. Harrison, K.N. Flentie, F.L. Henry, T. Wixe, P. Demirel, S.K. Vagolu, J. Chatagnon, A. Machelart, P. Brodin, T. Tønjum, C.L. Stallings, and F. Almqvist. Journal of Medicinal Chemistry, 2023. 66(16): p. 11056-11077. PMID[37485869]. PMCID[PMC10461229].
[PubMed]. TB_08_2023.
25. Synthesis and Evaluation of Antimycobacterial Activity and Molecular Docking of 4-(Benzyloxy)benzaldehyde-3,5-dinitrobenzohydrazone: A Combined Experimental and Theoretical Approaches. Singh, R., P. Rawat, A. Gautam, M. Kumar, P. Bharati, S. Gautam, A. Ram, A. Darwari, N.R.F. Holguin, and R.N. Singh. Journal of Molecular Structure, 2023. 1293: 136135. ISI[001050825800001].
[WOS]. TB_08_2023.
26. Synthesis, Biological Evaluation and Docking Studies of Silicon Incorporated Diarylpyrroles as MmpL3 Inhibitors: An Effective Strategy Towards Development of Potent Anti-tubercular Agents. Vasudevan, N., Z. Motiwala, R. Ramesh, S.B. Wagh, R.D. Shingare, R. Katte, A. Anand, S. Choudhary, A. Kumar, R.S. Gokhale, K.A. Kulkarni, and D.S. Reddy. European Journal of Medicinal Chemistry, 2023. 259: 115633. PMID[37524010].
[PubMed]. TB_08_2023.
27. Synthesis and Structure-Activity Relationships of a New Class of Oxadiazoles Targeting DprE1 as Antitubercular Agents. Yadav, V.D., H.I. Boshoff, L. Trifonov, J.S.O. Roma, T.R. Ioerger, C.E. Barry, and S. Oh. ACS Medicinal Chemistry Letters, 2023. ISI[001048447300001].
[WOS]. TB_08_2023.
28. Targeting Mycobacterium tuberculosis: Synthesis, In Vitro and In Silico Evaluation of Novel N(1)-(Benzo[d]oxazol-2-yl)-N(4)-arylidine Compounds. Zawal, A.G., M.M. Abdel-Aziz, A.A. El-Shanawani, L.M. Abdel-Aziz, M. Taha, C. Simons, and S.S. Elbaramawi. Archiv Der Pharmazie, 2023. 356(8): p. e2300187. PMID[37279375].
[PubMed]. TB_08_2023.
Patent Citations
29. Preparation of Rifamycin Derivatives as Antibacterial Agents. Antraygues, K., M. Bourotte, G.E. Dale, O. Defert, B. Gioia, M. Gitzinger, S. Lociuro, M. Maingot, V. Trebosc, and N. Willand. Patent. 2023. WO2023-EP51991 2023144297: 84 pp.
[Patent]. TB_08_2023.
30. Selective Agents Targeting Mycobacterium Tuberculosis. Roy, S., R. Doerksen, T. Berida, C. Stallings, S. McKee, and C. Ducho. Patent. 2023. WO2023-US61619 2023147571: 98 pp.
[Patent]. TB_08_2023.